Skip to main content
. 2020 Dec 1;14:5315–5324. doi: 10.2147/DDDT.S278414

Figure 4.

Figure 4

Role of β-mangostin on PI3K/AKT/mTOR pathway regulation in glioma. C6 cells were pretreated with three concentrations of β-mangostin (6.25, 12.5, and 25 μM). (A-B) Western blot analysis of PI3K/AKT/mTOR pathway in C6 cells. (C-D) Western blot analysis of PI3K/AKT/mTOR pathway after adding the PI3K inhibitor, LY294002 in C6 cells. Data are the meanμSD for three independent experiments. **P<0.01 and *P<0.05 vs. controls. ##P<0.01 and #P<0.05 vs. “β-mangostin+LY294002.”